| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-807 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 |
| filingDate |
1991-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1994-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc52902760a49d76f742ffc62bb7d7bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9908c5d862468f4e3f54c452e9fc0b46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e18f7c7bc685d0eac3e57fae3415e8ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a4afc06443485e24d59620f23e8344 |
| publicationDate |
1994-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5276139-A |
| titleOfInvention |
Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones |
| abstract |
N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the radioimmune assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9524207-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5420010-A |
| priorityDate |
1991-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |